APICES acknowledged for its remarkable role in GGCP 081/21 Study

We are proud to announce that APICES has been acknowledged for its ongoing collaboration in the GGCP 081/21 study, an Observational retrospective study in Lung Cancer (NSCLC). This acknowledgement was highlighted in the Journal of Clinical and Translational Oncology.

APICES has contributed extensively to critical aspects throughout the trial, including data management, biostatistics, and medical writing activities.

This acknowledgment is a great motivation for the entire APICES team to continue the commitment we bring to every project we collaborate on. We sincerely thank Astrazeneca Spain and Dra. Maria Carmen Areses Manrique for giving us the opportunity to support the study as CRO and for including us acknowledgments. We also congratulate them and all investigators and patients on the GGCP 081/21 Study progress and results.

The GGCP 081/21 study aims to evaluate the effectiveness and safety of osimertinib as a first-line therapy in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) in a Spanish real-world setting.

For further information about the GGCP 081/21 Study, please visit: Real-world clinical experience with osimertinib in advanced EGFR-mutated non-small cell lung cancer | Clinical and Translational Oncology